Hoba Therapeutics' HB-097 for Sensorineural Hearing Loss

Led by CEO Torsten M. Madsen, Hoba Therapeutics is a biotech developing restorative treatments for chronic pain disorders and hearing loss.

The company is advancing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease.

The second drug candidate HB-097 is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.

→ Hoba Therapeutics Raises EUR 23M in Series A Funding

 

Always happy to see more research, at least. And hey, maybe they'll both help?

 

A little bit about the company. They are using neurotrophins. See the crossover to the cochlear auditory nerve degeneration thread's findings.

→ https://hobatherapeutics.com/